{"id":"dextropropoxyphene-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Drowsiness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Cardiac arrhythmias"},{"rate":null,"effect":"Respiratory depression"}]},"_chembl":{"chemblId":"CHEMBL1213351","moleculeType":"Small molecule","molecularWeight":"339.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a synthetic opioid, dextropropoxyphene acts as an agonist at mu opioid receptors, which are distributed throughout the brain and spinal cord. This binding modulates pain signal transmission and produces analgesia. It is the active d-isomer of propoxyphene and was commonly used for mild to moderate pain relief, though it has been withdrawn from many markets due to safety concerns including cardiac arrhythmias and overdose risk.","oneSentence":"Dextropropoxyphene is an opioid analgesic that binds to mu opioid receptors in the central nervous system to reduce pain perception.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:38.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate pain"}]},"trialDetails":[{"nctId":"NCT00652093","phase":"PHASE4","title":"Lumbar Stenosis Outcomes Research II","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2008-03","conditions":"Lumbar Spinal Stenosis","enrollment":24},{"nctId":"NCT00378937","phase":"PHASE4","title":"Oxycodone or Standard Pain Therapy in Treating Patients With Cancer Pain","status":"COMPLETED","sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","startDate":"2004-01","conditions":"Pain, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":30}],"_emaApprovals":[],"_faersSignals":[{"count":22,"reaction":"CONDITION AGGRAVATED"},{"count":18,"reaction":"NAUSEA"},{"count":17,"reaction":"DYSPNOEA"},{"count":16,"reaction":"RENAL FAILURE"},{"count":15,"reaction":"ASTHENIA"},{"count":15,"reaction":"PAIN"},{"count":14,"reaction":"DIZZINESS"},{"count":14,"reaction":"DRUG INTERACTION"},{"count":14,"reaction":"HEADACHE"},{"count":14,"reaction":"PYREXIA"}],"_approvalHistory":[],"publicationCount":30,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"dextropropoxyphene hydrochloride","genericName":"dextropropoxyphene hydrochloride","companyName":"University Hospitals Bristol and Weston NHS Foundation Trust","companyId":"university-hospitals-bristol-and-weston-nhs-foundation-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dextropropoxyphene is an opioid analgesic that binds to mu opioid receptors in the central nervous system to reduce pain perception. Used for Mild to moderate pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}